<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918450</url>
  </required_header>
  <id_info>
    <org_study_id>M10-738</org_study_id>
    <nct_id>NCT00918450</nct_id>
  </id_info>
  <brief_title>Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen</brief_title>
  <official_title>A Phase 2b Monotherapy Study of ABT-263 in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      This is a Phase 2b, open-label, multicenter, global study assessing the safety and efficacy
      of ABT-263 in subjects with B-cell CLL who have failed at least one prior
      fludarabine-containing regimen.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor has decided to not proceed with this study.
  </why_stopped>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety of ABT-263 by evaluating study drug exposure, adverse events, serious adverse events, all deaths, as well as changes in laboratory determinations and vital sign parameters.</measure>
    <time_frame>monthly (at a minimum)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the objective response rate (partial response [PR] and confirmed complete response [CR]) of B-cell CLL subjects treated with ABT-263.</measure>
    <time_frame>Every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the effects of ABT-263 on duration of overall response, PFS and overall survival in subjects with B-cell CLL.</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effects of ABT-263 on time to response, 12-month survival rate, time to disease progression (TTP), and disease control rate in subjects with B-cell CLL .</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the effects of ABT-263 on quality of life (FACT-Leu and EQ-5D), ECOG performance status, and biomarkers in subject with B-cell CLL.</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Continuous dosing until disease progression using one of the following formulations:
25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 18 yrs of age, have B-cell CLL, failed at least 1 prior fludarabine-containing
             regimen.

          -  Refractory to 1 fludarabine-containing regimen is defined as failure to achieve at
             least PR to the last fludarabine-containing regimen received, or disease progression
             while receiving the last fludarabine-containing regimen, or disease progression in
             responders (i.e., achieved a PR or CR) within 6 mos of the last cycle of the last
             fludarabine-containing regimen received (e.g., fludarabine monotherapy, FR, or FC) or
             in responders (i.e., achieved a PR or CR ) within 24 mos of the last cycle of FCR.

          -  Intolerant to fludarabine is defined as discontinuation of therapy within 2 cycles due
             to side effects/toxicity from the last fludarabine-containing regimen.

          -  ECOG score of &lt;=1.

          -  Adequate coagulation, renal, &amp; hepatic function at Screening as follows:

               -  Serum creatinine &lt;= 2.0 mg/dL or calculated creatinine clearance &gt;= 50 mL/min;

               -  AST &amp; ALT &lt;= 3.0 x ULN;

               -  Bilirubin &lt;= 1.5 x ULN.

          -  Gilbert's Syndrome may have a Bilirubin &gt; 1.5 x ULN; aPTT, PT, not to exceed 1.2 x
             ULN.

          -  Adequate bone marrow (BM) independent of any growth factor support (with the exception
             of subjects with BM heavily infiltrated with underlying disease [80% or more] who may
             use growth factor support to achieve adequate BM) at Screening as follows:

               -  ANC &gt;= 1000/µL;

               -  Platelets &gt;= 75,000/mm3 (entry platelet count must be independent of transfusion
                  within 14 days of Screening);

               -  Hemoglobin &gt;= 9.0 g/dL.

          -  History of autologous BM transplant must be &gt; 6 mos post transplant (prior to the 1st
             dose of study drug) &amp; have adequate BM independent of any growth factor support (with
             the exception of subjects with BM that is heavily infiltrated with underlying disease
             [80% or more] who may use growth factor support to achieve adequate BM) at Screening
             as follows:

               -  ANC &gt;= 1500/µL;

               -  Platelets &gt;= 125,000/mm3;

               -  Hemoglobin &gt;= 10.0 g/dL.

          -  Female subjects must be surgically sterile, postmenopausal (at least 1 year), or have
             negative results on a pregnancy test.

          -  All female subjects not surgically sterile or postmenopausal (at least 1 year) &amp;
             non-vasectomized male subjects must practice birth control.

        Exclusion Criteria:

          -  History/clinically suspicious for cancer-related CNS disease.

          -  Undergone allogeneic stem cell transplant.

          -  Undergone autologous stem cell transplant w/i 6 mos prior to 1st dose.

          -  History/predisposing condition of bleeding or currently exhibits signs of bleeding.

          -  Recent history of non-chemotherapy induced thrombocytopenic associated bleeding w/i 6
             mos prior to 1st dose.

          -  Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.

          -  Active immune thrombocytopenic purpura or history of being refractory to platelet
             transfusions w/i 1 yr prior to 1st dose.

          -  Currently receiving/requires anticoagulation therapy or any drugs or herbal
             supplements that affect platelet function, with the exception of low-dose
             anticoagulation medications used to maintain the patency of a central IV catheter.

          -  Significant history of cardiovascular disease, renal, neurologic, psychiatric,
             endocrinologic, metabolic, immunologic, or hepatic disease.

          -  Positive for HIV, Hepatitis B, or Hepatitis C.

          -  Previous or current malignancies w/i the last 3 yrs:

               -  except adequately treated in situ carcinoma of the cervix uteri;

               -  basal or squamous cell carcinoma;

               -  in situ carcinoma of the bladder;

               -  or previous malignancy confined and surgically resected with curative intent.

          -  Has Prolymphocytic leukemia or Richter's transformation to an aggressive B-cell
             malignancy.

          -  Exhibits evidence of other clinically significant uncontrolled condition(s) including,
             but not limited to uncontrolled systemic infection or diagnosis of fever and
             neutropenia w/i 1 week prior to study drug.

          -  Prior exposure to ABT-263.

          -  Received antibody therapy w/i 30 days prior to 1st dose.

          -  Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy,
             hormonal, or any investigational therapy w/i 14 days prior to the 1st dose, or has not
             recovered to &lt;Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.

          -  Received steroid therapy for anti-neoplastic intent, w/i 7 days prior to the 1st dose
             with the exception of inhaled steroids for asthma, topical steroids, or
             replacement/stress corticosteroids.

          -  Received aspirin w/i 7 days prior to the 1st dose.

          -  Consumed grapefruit or grapefruit products w/i 3 days prior to 1st dose.

          -  Females pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>February 25, 2010</last_update_submitted>
  <last_update_submitted_qc>February 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sari Enschede, MD</name_title>
    <organization>Abbott Laboratories</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

